Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure

Journal of the American College of Cardiology

Volumn 47, Issue 2, 2006, Pages 332-337

  Sola, Srikanth ^a   Mir, Muhammad Q S ^a   Lerakis, Stamatios ^c   Tandon, Neeraj ^b   Khan, Bobby V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 6; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ERYTHROCYTES; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PILOT PROJECTS; PYRROLES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STROKE VOLUME; SUPEROXIDE DISMUTASE; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 30344431522     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.088     Document Type: Article

References (35)

1. A. Deswal, N.J. Petersen, A.M. Feldman Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the VESnarinone Trial (VEST) Circulation 103 2001 2055 2059
2. M. Rauchhaus, W. Doehner, D.P. Francis Plasma cytokine parameters and mortality in patients with heart failure Circulation 102 2000 3060 3067
3. A. Deswal, N.J. Petersen, A.M. Feldman Cytokines and cytokine receptors in advanced heart failure an analysis of the cytokine database from the VESnarinone Trial (VEST) Circulation 103 2001 2055 2059
4. K. Kaneko, T. Kanda, Y. Yamauchi C-reactive protein in dilated cardiomyopathy Cardiology 91 1999 215 219
5. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
6. F.M. Sacks, M.A. Pfeffer, L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
7. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
8. The Heart Protection Study Collaborative Group The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomized placebo controlled trial Lancet 360 2002 7 22
9. J.K. Kjekshus, T.R. Pedersen, A.G. Olsson The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J Card Fail 3 1997 249 254
10. T.B. Horwich, W.R. MacLellan, G.C. Fonarow Statin therapy is associated with improved survival in ischemic and nonischemic heart failure J Am Coll Cardiol 43 2004 642 648
11. H. Drexler, B.D. Horning Endothelial dysfunction in human disease J Mol Cell Cardiol 31 1999 51 60
12. K.K. Koh Effects of statins on vascular wall vasomotor function, inflammation, and plaque stability Cardiovasc Res 47 2000 648 657
13. D.J. Lefer Statins as potent anti-inflammatory drugs Circulation 106 2002 2041 2042
14. S. Hayashidani, H. Tsutsui, T. Shiomi Fluvastatin, a 3-hyroxy-3- methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 105 2002 868 873
15. R.B. Devereaux, N. Reichek Echocardiographic determination of left ventricular mass in man Circulation 55 1977 613 618
16. O. Erel, A. Kocyigit, V. Bulut, M.S. Gurel Reactive nitrogen and oxygen intermediates in patients with cutaneous leishmaniasis Mem Inst Oswaldo Cruz 94 1999 179 183
17. M. Porsch-Oezcueruemez, D. Kunz, H. Kloer Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease J Am Coll Cardiol 34 1999 1995 2001
18. J.K. Kjekshus, T.R. Pedersen, A.G. Olsson The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J Card Fail 3 1997 249 254
19. W.S. Aronow, C. Ahn Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol <125 mg/dl treated with statins versus no lipid lowering drug Am J Cardiol 90 2002 147 149
20. D. Mozaffarian, R. Nye, W.C. Levy Statin therapy is associated with lower mortality among patients with severe heart failure Am J Cardiol 93 2004 1124 1129
21. L.B. Mitchell, J.L. Powell, A.M. Gillis Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial J Am Coll Cardiol 42 2003 81 87
22. A. Hognestad, K. Dickstein, E. Myhre Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure Am J Cardiol 93 2004 603 606
23. T.B. Horwich, W.R. MacLellan, G.C. Fonarow Statin therapy is associated with improved survival in ischemic and nonischemic heart failure J Am Coll Cardiol 43 2004 642 648
24. J.G. Ray, Y. Gong, K. Sykora, J.V. Tu Statin use and survival outcomes in elderly patients with heart failure Arch Intern Med 165 2005 62 67
25. K. Node, M. Fujita, M. Kitakaze Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 2003 839 843
26. D.L. Mann Inflammatory mediators and the failing heart past, present, and the foreseeable future Circ Res 91 2002 988 998
27. S. von Haehling, E.A. Jankowska, S.D. Anker Tumour necrosis factor-alpha and the failing heart pathophysiology and therapeutic implications Basic Res Cardiol 99 2004 18 28
28. S.D. Anker, P. Ponikowski, S. Varney Wasting as independent risk factor for mortality in chronic heart failure Lancet 349 1997 1050 1053
29. S.D. Anker, M. Rauchhaus Insights into the pathogenesis of chronic heart failure immune activation and cachexia Curr Opin Cardiol 14 1999 211 216
30. M.H. Shishehbor, R.J. Aviles, M.L. Brennan Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy JAMA 289 2003 1675 1680
31. M.H. Shishehbor, M. Brennan, R.J. Aviles Statins promote potent systemic antioxidant effects through specific inflammatory pathways Circulation 29 2003 426 431
32. J. Bauersachs, P. Galuppo, D. Fraccarollo Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure Circulation 104 2001 982 985
33. R.U. Pliquett, K.G. Cornish, J.D. Peuler Simvastatin normalizes autonomic neural control in experimental heart failure Circulation 107 2003 2493 2498
34. MERIT-HF Study Group Effect of Metoprolol CR/XL in chronic heart failure Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
35. K. Dickstein, J.K. Kjekshus Comparison of baseline data, initial course, and management Losartan versus Captopril following acute myocardial infarction (the OPTIMAAL trial) Am J Cardiol 97 2001 766 771